Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Lung Cancer
Conference Highlights ASCO
,
Lung Cancer
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Read More
COVID-19
,
Lung Cancer
Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care
Walter Alexander
Read More
Lung Cancer
EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History
Walter Alexander
Read More
FDA Approvals
,
Lung Cancer
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
Lung Cancer
Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
Read More
Lung Cancer
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
Phoebe Starr
Read More
Lung Cancer
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Approvals
,
Lung Cancer
,
Select Drug Profiles
Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma
Read More
1
2
3
4
Page 1 of 5
Results 1 - 10 of 44